Ambrose CS - Search Results

1

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS. Anderson EJ, et al. Among authors: ambrose cs. Am J Perinatol. 2020 Mar;37(4):421-429. doi: 10.1055/s-0039-1681014. Epub 2019 Apr 16. Am J Perinatol. 2020. PMID: 30991438 Free article.

2

Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.

Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Block SL, et al. Among authors: ambrose cs. Vaccine. 2008 Sep 8;26(38):4940-6. doi: 10.1016/j.vaccine.2008.07.013. Epub 2008 Jul 26. Vaccine. 2008. PMID: 18662737 Clinical Trial.

3

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, Sifakis F, Groothuis JR. Ambrose CS, et al. Pediatr Infect Dis J. 2014 Jun;33(6):576-82. doi: 10.1097/INF.0000000000000219. Pediatr Infect Dis J. 2014. PMID: 24622396 Free PMC article.

4

Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.

McLaurin K, Ambrose CS. McLaurin K, et al. Among authors: ambrose cs. Pediatrics. 2014 Apr;133(4):e1101. doi: 10.1542/peds.2014-0077A. Pediatrics. 2014. PMID: 24692037 No abstract available.

5

Methods to estimate gestational age can significantly affect study results.

Ambrose CS, Rizzo C, Caspard H. Ambrose CS, et al. JAMA Pediatr. 2014 Apr;168(4):388. doi: 10.1001/jamapediatrics.2013.5175. JAMA Pediatr. 2014. PMID: 24710585 No abstract available.

6

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.

Ambrose CS, Chen X, Kumar VR. Ambrose CS, et al. Hum Vaccin Immunother. 2014;10(10):2785-8. doi: 10.4161/hv.32082. Epub 2014 Nov 21. Hum Vaccin Immunother. 2014. PMID: 25483483 Free PMC article. Clinical Trial.

7

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS. Forbes ML, et al. Among authors: ambrose cs. Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635. Hum Vaccin Immunother. 2014. PMID: 25483663 Free PMC article. Clinical Trial.

8

Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis.

Simões EA, Ambrose CS, Wu X, Anderson EJ. Simões EA, et al. Among authors: ambrose cs. Pediatr Infect Dis J. 2015 Mar;34(3):331. doi: 10.1097/INF.0000000000000566. Pediatr Infect Dis J. 2015. PMID: 25742086 No abstract available.

9

Standard methods based on last menstrual period dates misclassify and overestimate US preterm births.

Ambrose CS, Caspard H, Rizzo C, Stepka EC, Keenan G. Ambrose CS, et al. J Perinatol. 2015 Jun;35(6):411-4. doi: 10.1038/jp.2015.25. Epub 2015 Apr 2. J Perinatol. 2015. PMID: 25836319

10

The Medicaid Cost of Palivizumab.

Ambrose CS, McLaurin KK. Ambrose CS, et al. J Pediatric Infect Dis Soc. 2015 Mar;4(1):83-4. doi: 10.1093/jpids/piu025. Epub 2014 Apr 2. J Pediatric Infect Dis Soc. 2015. PMID: 25844167 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters